1. Home
  2. CHNR vs ACXP Comparison

CHNR vs ACXP Comparison

Compare CHNR & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo China Natural Resources Inc.

CHNR

China Natural Resources Inc.

HOLD

Current Price

$3.90

Market Cap

4.9M

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

SELL

Current Price

$1.04

Market Cap

5.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CHNR
ACXP
Founded
N/A
2017
Country
China
United States
Employees
9
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9M
5.8M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
CHNR
ACXP
Price
$3.90
$1.04
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
1.2K
★ 84.4K
Earning Date
11-24-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$0.95
52 Week High
$5.80
$7.54

Technical Indicators

Market Signals
Indicator
CHNR
ACXP
Relative Strength Index (RSI) 46.19 40.18
Support Level $3.60 N/A
Resistance Level $3.93 $1.77
Average True Range (ATR) 0.06 0.07
MACD -0.01 0.01
Stochastic Oscillator 0.00 48.53

Price Performance

Historical Comparison
CHNR
ACXP

About CHNR China Natural Resources Inc.

China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: